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Rationale: The relationship between kidney function and venous thromboembolism (VTE) in critically ill patients
is not well studied. The main objective of this study was to evaluate this relationship in patients admitted to a
medical-surgical intensive care unit (ICU).
Methods: This was a retrospective study of 798 patients admitted to a tertiary-care ICU and prospectively followed
for the development of clinically suspected and radiologically diagnosed deep venous thrombosis or pulmonary
embolism. Patients were divided based on admission creatinine and dialysis history into ﬁve groups: normal kid-
ney function, RIFLE classes R, I and F (combined = acute kidney injury [AKI]) and endstage renal disease (ESRD).
We compared VTE prophylaxis practices and VTE incidence in these groups and evaluated renal failure as a VTE
risk factor using multivariate Cox regression analysis.
Results:Of the 798 patients, 27.2% had AKI and 10.1% had ESRD. Unfractionated heparin use was similar in the ﬁve
groups but enoxaparin usewas less frequent in AKI (13.4%) and ESRD (3.8%) patients comparedwith patientswith
normal kidney function (39.0%). VTE occurred in 7.6% of patientswith normal renal function, 7.8% AKI patients and
2.5% ESRD patients (p = 0.22). The adjusted hazard ratios for VTE compared to patients with normal kidney func-
tion were 0.35 (95% conﬁdence interval [CI], 0.08-1.47) for RIFLE class R, 1.19 (95% CI, 0.83-1.70) for RIFLE class I,
0.82 (95% CI, 0.59-1.14) for RIFLE class F and 0.71 (95% CI, 0.49-1.02, p = 0.06) for ESRD.
Conclusions: Neither AKI nor ESRD was an independent risk factors for critically ill patients.© 2013 The Authors. Published by Elsevier Ltd. Open access under CC BY-NC-ND license. Introduction
Critically ill patients are at increased risk for venous thromboembo-
lism (VTE) [1,2] during their stay in the intensive care unit (ICU). Addi-
tionally, many of them either have chronic kidney disease (CKD) or
develop acute kidney injury (AKI) [3]. Studies that evaluated the
relationship between the kidney function and VTE are scarce. A
community-based population study of non-dialysis-dependent patientsent, King Abdulaziz Medical
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.Open access under CC BY-NC-ND licefound that after adjustment for age, gender, race and center, the relative
risk for VTE was 1.28 (95% conﬁdence interval [CI], 1.02-1.59) for those
with mildly decreased kidney function and 2.09 (95% CI, 1.47-2.96)
for those with stage 3/4 CKD, compared with people with normal
kidney function [4]. A large 1996 US cohort study found that end-
stage kidney disease (ESRD) was associated with 2.1 increased risk
of pulmonary embolism (PE) compared to the general population
[5]. Whether kidney function is a risk factor for VTE in critically ill
patient is not well studied. A prospective cohort study evaluated
the incidence of proximal lower extremity deep venous thrombosis
(DVT) in 261 critically ill patients using periodic ultrasonographic
screening and found that ESRD, but not AKI, was associated with
increased DVT risk (hazard ratio [HR], 3.7; 95% CI,1.2-11.1) [2]. PE
was not evaluated in this study [2].
Because of the paucity of evidence, we evaluated the relationship
between VTE and both AKI and ESRD using data from a prospective
cohort of medical and surgical ICU patients followed for the develop-
ment of VTE. Additionally, we reported the incidence of VTE and de-
scribed VTE prophylaxis practices according to kidney function on ICU
admission.nse. 
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Patients and Setting
Thiswas a post-hoc analysis of data fromaprospective observational
cohort study performed to determine the incidence, predictors and out-
comes of VTE in critically ill patients [6]. The cohort was comprised of
798 consecutive adult patients (age ≥ 18 years) admitted to the ICU
of King Abdulaziz Medical City between July 2006 and January 2008
and expected to stay in the ICU for more than 48 hours. The ICU was a
closed medical and surgical ICU staffed by board-certiﬁed critical care
physicians 24 hours per day, 7 days per week. The hospital was a 900-
bed tertiary-care academic center in Riyadh, Saudi Arabia, had been
accredited by Joint Commission International and had its own
thromboprophylaxis guidelines. These patients were followed for the
development of VTE (both DVT and PE) during ICU stay and up to
5 days after ICU discharge to the wards. DVT was diagnosed by Doppler
compression ultrasound of extremities and PE by spiral computerized
tomography of the chest or lung ventilation-perfusion scans. These
tests were ordered at the discretion of the treating intensivist when
VTE was clinically suspected. Patients were excluded if they had any
of the following: Do-Not-Resuscitate order or brain death within
24 hours of admission, chronic anticoagulation with warfarin or hepa-
rin, admission to the ICU with acute PE or DVT diagnosed on admission
or within ﬁrst 24 hours of ICU admission. The original study was ap-
proved by the Institutional Review Board of King Abdulaziz Medical
City-Riyadh.
Data Collection
The following baseline information were noted: patients’ demo-
graphics including age, gender, body mass index, Acute Physiology
and Chronic Health Evaluation (APACHE) II [7], admitting diagnostic
category (respiratory, cardiovascular, neurological, other medical illness,
trauma and postoperative), admission Glasgow Coma Scale (GCS) score,
admission creatinine, bilirubin, lactate, platelet count and International
Normalized Ratio (INR) and pre-deﬁned VTE risk factors. In addition,
the following data were collected on a daily basis for a period of
30 days or until ICU discharge to the wards or mortality, whichever
earlier: use of pharmacologic thromboprophylaxis (unfractionated
heparin or low molecular weight heparin [enoxaparin]), the use of
mechanical thromboprophylaxis (graduated compression stockings
and intermittent pneumatic compression device), number and loca-
tion of central lines, and requirement for mechanical ventilation and
renal replacement therapy. The primary outcome of this study was
the incidence of VTE among critically ill patients according to kidney
function. The secondary outcomes were VTE prophylaxis practices, ICU
and hospital mortality, ICU and hospital length of stay (LOS), and dura-
tion of mechanical ventilation.
Categorization of Patients According to Renal Function
For the purpose of this study, patients who had chronic renal failure
requiring dialysis before ICU admission were classiﬁed as ESRD. The
other patients were divided into four groups according to the RIFLE clas-
siﬁcation of kidney function. For this classiﬁcation, baseline creatinine
was estimated using back-calculation with the Modiﬁcation of Diet in
Renal Disease (MDRD) formula as per the following equation [8]: esti-
mated baseline creatinine = (GFR/[186 x age -0.203 x Sex x Race]) -0.867
(mg/dL), where the glomerular ﬁltration rate (GFR) is the baseline GFR
assumed to be 75 ml/min [9]; Sex = 1 if male and 0.742 if female;
Race = 1.21 if black, otherwise Race = 1; and Age is in years. Patients
were classiﬁed as having normal kidney function if admission creatinine
was≤1.5x estimated baseline creatinine. The other patients had AKI and
were divided into RIFLE class R (Risk) if admission creatinine was N1.5x
estimated creatinine but b2x, class I (Injury) if admission creatininewas ≥2x estimated baseline creatinine but b3x and class F (Failure) if
admission creatinine ≥3x estimated baseline creatinine [9,10].
Statistical Analysis
Statistical analysis was performed using the Statistical Analysis
Software (SAS, Release 8, SAS Institute Inc., Cary, NC, 1999, USA).
Baseline characteristics and clinically relevant interventions of pa-
tients, as well as outcomes, in the ﬁve groups were summarized by
providing the numbers and percentages for categorical variables
and mean and standard deviation for continuous variables. The
Chi-square test was used to assess differences among groups for
categorical variables and ANOVA test for continuous variables. To
evaluate if kidney function was a risk factor for VTE, proportional
Cox regression analysis was performed with patients with normal
renal function on ICU admission being the reference group. Baseline
demographic and clinical characteristics that were signiﬁcantly dif-
ferent among the patients with the different kidney function groups,
VTE risk factors and thromboprophylaxis practices were entered in
the model. These variables were age, gender, body mass index,
admission APACHE II score, admission diagnostic categories, plate-
lets count, INR, mechanical ventilation, bedridden status before
admission, admission related to femur/hip fracture or surgery,
presence and location of central venous catheter, use of oral contra-
ceptives, history of venous insufﬁciency, presence of sepsis on ad-
mission, spinal cord injury, history of malignancy, history of
congestive heart failure, history of recent surgery, history of previous
PE or DVT, previous stroke, use of mechanical prophylaxis, use of
unfractionated heparin and low molecular weight heparin for
thromboprophylaxis. The results are presented as adjusted HRs
with 95% CI. P-values b 0.05 were considered signiﬁcant for all
analyses.
Results
Baseline Characteristics and VTE Risk Factors
Of the 798 patients in the cohort, 37.3% had abnormal renal func-
tion on ICU admission, with 217 (27.2%) patients having AKI (8.0%
RIFLE class R, 9.2% RIFLE class I and 10.0% RIFLE class F) and 10.1%
having ESRD. Table 1 describes the characteristics of patients
according to RIFLE classiﬁcation. Patients with renal failure were
older and had higher APACHE II score. Patients with renal failure
were more likely to be admitted because of cardiovascular disease
and sepsis and were less likely to be admitted postoperatively.
Most patients required mechanical ventilation with no signiﬁcant
difference among the different groups. Renal replacement therapy
was required during ICU stay for 4.0% of patients who had normal
kidney function on admission, compared with 41.5% of with AKI
patients (RIFLE classes R, I and F). Additionally, there were signiﬁ-
cant imbalances in other VTE risk factors among the three patient
groups as described in Table 1.
Practices of VTE Prophylaxis
Table 2 describes thromboprophylaxis practices according to kidney
function on ICU admission. The use of unfractionated heparin was sim-
ilar in the ﬁve groups. Patients with renal failure received enoxaparin
less frequently (13.4% of AKI patients and 3.8% of ESRD patients) com-
pared with patients with normal kidney function (39.0%). Recent
surgery, intracranial hemorrhage and other bleeding risks were the
most common reasons cited for not administering pharmacologic
prophylaxis. Graduated compression stockings were applied for similar
proportions of patients in the different kidney function groups. Howev-
er, there weremore differences in the rate of application of intermittent
pneumatic compression devices. Moreover, the percentage of patients
Table 1
Baseline characteristics and venous thromboembolism risk factors of patients in the cohort categorized according to renal function on admission to the intensive care unit.
All patients
N = 798
Normal kidney function
N = 500
RIFLE class R
N = 64
RIFLE class I
N = 73
RIFLE class F
N = 80
ESRD
N = 81
P-value
Age (years), mean ± SD 50.2 ± 21.2 42.9 ± 20.9 60.5 ± 18.4 66.0 ± 14.0 61.8 ± 15.0 61.3 ± 13.1 b0.0001
Female gender, N (%) 263 (33.0) 125 (25.0) 32 (50.0) 34 (46.6) 38 (47.5) 34 (42.0) b0.0001
Body mass index (Kg/m2), mean ± SD 28.5 ± 10.2 27.1 ± 10.2 29.8 ± 8.7 31.7 ± 13.4 32.0 ± 9.2 28.8 ± 7.0 b0.0001
Admission GCS score, mean ± SD 8.6 ± 4.1 8.3 ± 4.0 8.3 ± 3.7 8.8 ± 4.2 9.0 ± 4.6 10.0 ± 4.2 0.03
APACHE II, mean ± SD 24.0 ± 9.0 20.2 ± 7.1 27.4 ± 8.3 30.9 ± 8.6 32.6 ± 8.0 30.0 ± 7.7 b0.0001
Admitting Diagnostic Category, N (%) b0.0001
Respiratory 169 (21.2) 97 (19.4) 14 (21.9) 15 (20.6) 26 (32.5) 17 (21.0)
Cardiovascular 246 (30.8) 95 (19.0) 26 (40.6) 39 (53.4) 37 (46.2) 49 (60.5)
Neurological 57 (7.1) 36 (7.20) 7 (10.9) 5 (6.8) 5 (6.2) 4 (4.9)
Other medical illness 36 (4.5) 12 (2.40) 9 (14.06) 3 (4.1) 79 (8.75) 5 (6.2)
Non-operative Trauma 123 (15.4) 121 (24.2) 1 (1.6) 1 (1.4) 0 (0) 0 (0)
Post-operative 167 (20.9) 139 (27.8) 7 (10.9) 10 (13.7) 5 (6.2) 6 (7.4)
Trauma (nonoperative and postoperative), N (%) 226 (28.3) 214 (42.8) 4 (6.2) 3 (4.11) 2 (2.5) 3 (3.7) b0.0001
Sepsis on admission, N (%) 321 (40.2) 131 (26.2) 41 (64.1) 49 (67.1) 47 (58.8) 53 (65.4) b0.0001
Creatinine⁎⁎ (μmol/L), mean ± SD 159 ± 145 82 ± 26 146 ± 28 203 ± 39 393 ± 175 377 ± 174 b0.0001
Bilirubin⁎⁎ (μmol/L)), mean ± SD 58 ± 128 36 ± 75 67 ± 156 102 ±186 84 ± 170 109 ± 188 b0.0001
Lactate (mmol/L), mean ± SD 3.3 ± 3.3 2.8 ± 2.4 3.9 ± 4.3 4.1 ± 3.6 4.5 ± 4.9 3.2 ± 3.7 b0.0001
Platelet count (109/L), mean ± SD 244 ± 156 259 ± 158 236 ± 151 215 ± 137 218 ± 160 212 ± 145 0.01
INR, mean ± SD 1.4 ± 0.7 1.3 ± 0.6 1.4 ± 0.5 1.7 ± 1.1 1.6 ± 0.8 1.6 ± 0.8 b0.0001
Bedridden for more 3 days before admission, N (%) 394 (49.4) 205 (41.0) 39 (60.9) 47 (64.4) 47 (58.8) 56 (69.1) b0.0001
Congestive heart failure, N (%) 38 (4.8) 10 (2.0) 4 (6.2) 8 (11.0) 10 (12.5) 6 (7.4) b0.0001
Active malignancy, N (%) 94 (11.8) 70 (14.0) 5 (7.8) 9 (12.3) 9 (11.2) 1 (1.2) 0.02
History of stroke, N (%) 106 (13.3) 49 (9.8) 14 (21.9) 14 (19.2) 14 (17.5) 15 (18.5) 0.004
Recent surgery, N (%) 243 (30.4) 193 (38.6) 9 (14.1) 18 (24.7) 13 (16.2) 10 (12.4) b0.0001
Previous PE or DVT, N (%) 12 (1.5) 3 (0.6) 1 (1.6) 2 (2.7) 4 (5.0) 2 (2.5) 0.03
Femur/pelvic fracture or hip/knee replacement, N (%) 52 (6.5) 47 (9.4) 0 (0) 3 (4.1) 2 (1.2) 1 (1.2) 0.001
Spinal cord injury, N (%) 20 (2.5) 18 (3.6) 1 (1.6) 0 (0) 0 (0) 1 (1.2) 0.13
Central venous catheter⁎, N (%) 595 (74.6) 356 (71.2) 49 (76.6) 58 (79.4) 66 (82.5) 66 (81.5) 0.07
Central venous catheter location, N (%)
Femoral vein 342 (42.9) 172 (34.4) 26 (40.6) 36 (49.3) 57 (71.2) 51 (63.0) b0.0001
Subclavian or internal jugular vein 525 (65.8) 315 (63.0) 46 (71.9) 50 (68.5) 59 (73.8) 55 (67.9) 0.25
Mechanical ventilation, N (%) 687 (86.1) 437 (87.4) 59 (92.2) 59 (80.8) 67 (83.8) 65 (80.2) 0.13
Renal replacement therapy, N (%) 191 (23.9) 20 (4.0) 16 (25.0) 24 (32.9) 50 (62.5) 81 (100) b0.0001
APACHE, Acute Physiology and Chronic Health Evaluation; DVT, deep venous thrombosis; ESRD, end-stage renal disease; GCS, GlasgowComa Scale; PE, pulmonary embolism; SD, standard
deviation.
⁎ includes hemodialysis catheters.
⁎⁎ To convert creatinine to mg/dl divide by 88.4, bilirubin to mg/dL divide by 17.1, lactate to mg/dl divide by 0.111.
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ﬁve groups.Outcomes of Patients
Table 3 describes the outcomes of the patients in the cohort
according to their kidney function on admission to the ICU. VTE oc-
curred in 38 (7.6%) patients with normal renal function, 17 (7.8%) AKI
patients and 2 (2.5%) ESRD patients (p = 0.22). The incident rates of
VTE were 3.6 per 1000 patient-days for patients with normal kidney
function, 1.4 per 1000 patient-days for patients with RIFLE class R (inci-
dence rate ratio with normal kidney function being the reference, 0.37;
95%CI, 0.09-1.55), 6.6 per 1000 patient-days for patients for RIFLE class I
(incidence rate ratio, 1.82; 95%CI, 0.91-3.65), 3.7 per 1000 patient-days
for RIFLE class F (incidence rate ratio, 1.02; 95%CI, 0.40-2.59) and 1.6 per
1000 patient-days for ESRD patients (incidence rate ratio, 0.44; 95%CI,
0.10-1.80).
Fig. 1 describes VTE incidence according to renal replacement thera-
py while in the ICU for different kidney function groups. For AKI
patients, those who needed renal replacement therapy had similar
VTE incidence compared to those who did not have it (8.9% and 7.1
respectively, p = 0.63).
On Cox regression analysis, AKI (RIFLE classes R, I and F) was not as-
sociated with increased VTE risk compared to normal kidney function
(adjustedHR, 0.85, 95% CI, 0.47-1.54). The adjusted HRs for the different
RIFLE classes were: 0.35 (95% CI, 0.08-1.47) for RIFLE class R, 1.190 (95%
CI, 0.83-1.70) for RIFLE class I and 0.82 (95% CI, 0.59-1.14) for RIFLE classF. ESRD was associated with adjusted HR of 0.71 (95% CI, 0.49-1.02,
p = 0.06) compared to normal kidney function.
Discussion
In this study, we did not ﬁnd signiﬁcant differences in VTE incidence
in patients with AKI, ESRD or normal kidney function. In addition, renal
replacement therapy while in the ICU did not seem to alter VTE inci-
dence. On multivariate analysis, neither ESRD nor any of the RIFLE clas-
ses of AKI was an independent risk factor for VTE in critically ill patients
during ICU stay.
Critically ill patients are at increased risk of VTE because of the
presence of multiple predisposing factors [1]. However, renal function
has not been well investigated in relationship to VTE development dur-
ing critical illness. Renal dysfunction includes a myriad of conditions,
such as nephrotic syndrome, AKI and ESRD. From pathophysiology
point of view, nephrotic syndrome is associated with a hypercoagulable
state and increased VTE risk (relative risk of PE, 1.39 and of DVT, 1. 72
compared to those who did not have this syndrome) [11]. ESRD is asso-
ciated with both tendencies for bleeding and for thrombosis [12]. On
onehand, it predisposes for bleeding diathesis, mainly due to abnormal-
ities of primary hemostasis, in particular, platelet dysfunction and
impaired platelet-vessel wall interaction [13]. On the other hand, it is
associated with pro-thrombotic state due to increased levels of von
Willebrand Factor, hyperﬁbrinogenemia, increased thrombin formation
and activation of coagulation during hemodialysis [13]. Some of these
physiologic changes are expected to affect AKI patients, but they are
not well studied in this population. In addition, patients requiring
Table 2
Practices of pharmacologic and mechanical thromboprophylaxis according to kidney function. Pharmacologic prophylaxis includes the use of unfractionated heparin and enoxaparin.
Normal kidney function
N = 500
RIFLE class R
N = 64
RIFLE class I
N = 73
RIFLE class F
N = 80
ESRD
N = 81
P-value
Pharmacologic prophylaxis⁎, N (%)
Unfractionated heparin 300 (60.0) 45 (70.3) 49 (67.1) 51 (63.8) 56 (70.0) 0.23
Low molecular weight heparin 195 (39.0) 11 (17.2) 10 (13.7) 8 (10.0) 3 (3.8) b0.0001
No pharmacologic prophylaxis during stay in the intensive care unit 77 (15.4) 13 (20.3) 21 (28.8) 25 (31.2) 23 (28.4) b0.0001
Cited reasons for not using pharmacologic prophylaxis⁎⁎, N (%)
Recent surgery 116 (23.2) 3 (4.7) 9 (12.3) 4 (5.0) 6 (7.4) b0.001
Intracranial hemorrhage 111 (22.2) 5 (7.8) 4 (5.5) 0 (0) 3 (3.7) b0.001
Other bleeding risk 81 (16.2) 26 (40.6) 32 (43.8) 31 (38.8) 27 (33.3) b0.001
Mechanical prophylaxis, N (%)
Graduated compression stockings 136 (27.2) 14 (21.9) 14 (19.2) 17 (21.2) 16 (20.0) 0.33
Intermittent pneumatic compression devices 169 (33.0) 28 (43.8) 25 (34.2) 15 (18.8) 18 (22.5) 0.005
No mechanical prophylaxis during stay in the intensive care unit 228(45.6) 28 (43.8) 37 (50.7) 49 (61.2) 47 (58.8) 0.03
Cited reasons for not using mechanical prophylaxis⁎, N (%)
Pharmacologic prophylaxis 213 (42.6) 27 (42.2) 31 (42.5) 36 (45) 32 (39.5) 0.97
Lower extremity fracture 20 (4.0) 1 (1.6) 0 (0) 0 (0) 0 (0) 0.04
No prophylaxis, N (%) 38 (7.6) 4 (6.3) 7 (9.6) 12 (15.0) 11 (13.6) 0.12
⁎ The same patient may have received unfractionated and low molecular weight heparin at different times during stay.
⁎⁎ Each patient could have more than one reason.
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tional VTE risk due to vascular access [14].
The hematologic changes associated with renal dysfunction may
affect physicians’ decision to use VTE prophylaxis and/or choice of pro-
phylaxis modality. This is supported by one study in which severe renal
failure with glomerular ﬁltration rate b 30 mL/min/m2 was associated
with increased risk of major bleeding and clinically relevant non-
major bleeding combined (OR, 2.14; 95% CI, 1.44-3.20) on multivariate
analysis [15]. A recent multinational cross-sectional study found that
acute renal failure was associated with less use of thromboprophylaxis
(aOR = 0.23, p b 0.05) [16]. However, another study that evaluated pa-
tients who had DVT found that thromboprophylaxis rates prior to DVT
were similarly low in CKD and non-CKD patients (44.2% vs. 38.0%,
p = 0.06) [17]. In our study the use of unfractionated heparin was sim-
ilar in all groups regardless of kidney function. As expected, we found
that low molecular weight heparin, enoxaparin, was less used in the
renal failure groups, especially in ESRD patients. Renal failure is associ-
ated with decreased clearance of enoxaparin compared to normal
renal function [18,19], which predisposes for acute bleeding. This has
led the American College of Chest Physicians to recommend to avoid
such an anticoagulant in the presence of renal impairment, to use a
lower dose, or to monitor its anticoagulant effect [20]. However, this is
not a class effect, as evidence suggests that dalteparin is not associated
with increased bleeding risk due to bioaccumulation [21].
We found that the VTE incidencewas not statistically different in the
different kidney function groups. Patients with RIFLE class I had the
highest VTE incidence (13.7%) and incidence rate (6.6 per 1000
patient-days) and ESRD patients to have the lowest incidence (2.5%).
The risk of VTE in ICU patients with severe renal insufﬁciency receiving
subcutaneous dalteparin was examined in a multicenter prospectiveTable 3
Outcomes of patients in the cohort according to kidney function.
Normal kidney function
N = 500
Venous thromboembolism, N (%) 38 (7.6)
PE and DVT, N (%) 2 (0.4)
DVT alone, N (%) 17 (3.4)
PE alone, N (%) 19 (3.8)
ICU Mortality, N (%) 68 (13.6)
Hospital Mortality, N (%) 125 (25.0)
ICU LOS (days), mean ± SD 16.7 ± 34.8
Hospital LOS (days), mean ± SD 75.8 ± 131.6
Mechanical ventilation duration (days), mean ± SD 9.9 ± 13.2
DVT, deep venous thrombosis; ESRD, endstage renal disease; ICU, intensive care unit; LOS, lencohort study. The study included 156 patients with a mean creatinine
clearance of 18.9 ± 6.5 ml/min who underwent bilateral compression
lower-limb venous ultrasound within 48 hours of study enrolment
and twice weekly thereafter [22]. VTE was diagnosed in 15 (9.6%) pa-
tients within 48 hours of ICU admission and in 5.1% during ICU stay
[22]. This study differs from our study as all patients were receiving
dalteparin, while our study reﬂects a real-life practice with patients re-
ceiving different prophylactic regimens. Additionally, this study utilized
screening ultrasounds, a strategy that is more sensitive in detecting
DVTs than our approach, which was based on clinical suspicion. Never-
theless, the results of the two studies conﬁrm that the risk of VTE in
patients with renal insufﬁciency is considerable even with using
thromboprophylaxis. Of note is that in our studyAKI patients had higher
INR and lower platelets compared to patients with normal kidney func-
tion, suggesting the presence of disseminated intravascular coagulation,
and more central catheters in femoral vein than patients with normal
kidney function. These factors may contribute to increased VTE risk.
However, when controlling for imbalances in baseline characteristics
and VTE risk factors, neither AKI nor ESRD was independently associat-
ed with VTE in ICU patients. These ﬁndings contrasted the ﬁndings of
two studies that suggested that ESRD was a VTE risk factor [2,5]. One
study was a large population-based cohort which found that ESRD
was associated with 2.1 increased PE risk compared to the general pop-
ulation [5]. The other one was a prospective cohort of critically ill med-
ical surgical patients which showed that ESRD was associated with
increased DVT risk (HR, 3.7; 95% CI, 1.2-11.1) [2]. It also found that
AKI was not a VTE risk factor [2], similar to what we found in our study.
Additionally, a large retrospective study of 1,015,598 cancer patients
from 133 U.S. medical centers between 1995 and 2003 found that
these patients had a VTE rate of 4.1% and that renal disease as a co-RIFLE class R
N = 64
RIFLE class I
N = 73
RIFLE class F
N = 80
ESRD
N = 81
P-value
2 (3.1) 10 (13.7) 5 (6.2) 2 (2.5) 0.056
1 (1.6) 1 (1.4) 0 (0) 1 (1.2) 0.59
1 (1.6) 6 (8.2) 5 (6.2) 0 (0) 0.04
0 (0) 3 (4.1) 0 (0.0) 1 (1.2) 0.27
21 (32.8) 25 (34.2) 30 (37.5) 27 (33.3) b0.0001
33 (51.6) 38 (52.8) 49 (61.2) 47 (59.5) b0.0001
19.7 ± 25.3 17.5 ± 20.0 13.8 ± 17.4 12.3 ± 13.2 0.55
64.5 ± 75.9 56.8 ± 65.4 52.0 ± 65.6 81.0 ± 149.0 0.34
13.4 ± 13.61 10.1 ± 10.3 9.2 ± 10.2 6.3 ± 6.4 0.014
gth of stay; PE, pulmonary embolism; SD, standard deviation.
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Fig. 1.Venous thromboembolism (VTE) incidence in patientswith normal kidney function
and acute kidney injury on admission to the intensive care unit according to the need for
renal replacement therapy (RRT) during stay. RRT included conventional hemodialyis and
continuous venovenous hemodialysis. There were 500 patients with normal kidney
function on admission, 64 patients with RIFLE class R, 73 patients with RIFLE class I and
80 patients with RIFLE class F.
675H.M. Al-Dorzi et al. / Thrombosis Research 132 (2013) 671–675morbid condition was an independent predictor of VTE development
(OR, 1.53; 95% CI,1.49-1.58) [23]. A community-based population
study of non–dialysis-dependent patients found that after adjustment
for age, gender, race, and center, the relative risk for VTE was 1.28
(95% CI, 1.02-1.59) for those with mildly decreased kidney function
and 2.09 (95% CI, 1.47-2.96) for those with stage 3/4 CKD, compared
with participants with normal kidney function [4]. Daneschvar and
colleagues compared the proﬁle of 268 CKD patients 4,307 patients
with preserved kidney function who had DVT and found that CKD
patients had upper extremity DVT more frequently than non-CKD
patients (30.0% vs. 10.8%, p b 0.0001) [17]. Regarding PE, evaluation of
the Nationwide Inpatient Sample found that patients with ESRD (527
per 100,000 persons) and CKD (204 per 100,000 persons) had higher
have PE rates than those with normal kidney function (66 per
100,000 persons) [24]. Additionally, a prospective study of patients
who had VTE showed that those with estimated glomerular ﬁltration
rate b 30 mL/min/1.73 m2 were at increased risk of VTE recurrence
(HR, 1.83; 95% CI, 1.03-3.25) [25].
The ﬁndings of this study should be interpreted in the light of its
strengths and limitations. Among its strengths is the prospective data
collection. Its limitations include the following: the studywas conducted
at one center; the sample size was small resulting inwide conﬁdence in-
terval in the results of regression analysis; we evaluated kidney function
on ICU admission, however, we evaluated VTE incidence in patients who
required renal replacement therapy during ICU stay; the investigation for
DVT or PE was done only when clinically suspected by the treating ICU
team, which may lead to the under-diagnosis of these conditions, how-
ever, this simulates day-to-day care in ICU as routine screening for DVT
is not recommended for most critically ill patients [20].
In conclusion, we found that neither AKI nor ESRD was an indepen-
dent risk factor for VTE in ICU patients. These patients should be treated
as general ICU patients regarding practices of pharmacologic and me-
chanical VTE prophylaxis taking into consideration the bleeding risk
and the guidelines for low molecular weight heparin use.Conﬂict of Interest Statement
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